Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. The acquisition, which is subject to customary closing conditions, including…
Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients with IgAnephropathy (IgAN). The study met its primary efficacy endpoint at…
Novartis today announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study at 9 months. Iptacopan, an investigational factor B inhibitor targeting the alternative complement pathway, demonstrated superiority versus placebo in proteinuria (protein in urine)…